Breaking 23:00 Killer Robots: Guterres Warns of Growing Threat Posed by Autonomous Weapons 22:30 Bharat Semi: Indian Chip Startup Raises $24 Million to Develop AI-Powered Sensors 22:15 Germany: EU Approves UniCredit’s Takeover of Commerzbank in Major Banking Consolidation Move 22:00 Yemen: Riyadh Dismisses Commander of the Military Coalition 21:30 Nvidia: Why Jensen Huang's Departure Could Shake the Entire AI Industry 21:00 Qatar Football: Walid Regragui Emerges as a Leading Candidate for National Team Coaching Job 20:30 Casablanca: Two Minors Sent to Child Protection Centre After Al Jabr School Terror Scare 20:00 Belgium: Romelu Lukaku Announces Retirement From International Football After 16 Years With the National Team 19:30 US Military Reinforcement: Third Aircraft Carrier Arrives in the Middle East Ahead of Trump’s China Summit 19:00 Morocco: Tomato Prices Remain High Despite Suspension of Exports to African Markets 18:30 Yemen: Houthis Advance Within 60 Kilometers of Aden as Government Reinforces Defences 18:00 Happy Passports Index 2026: Morocco Scores 29.7 Points and Ranks 49th 17:30 Casablanca: Building Collapse in Bouchentouf Damages Shops and Three Cars 17:00 AFCON 2027: Morocco Prepare for Crucial Niger Encounter With Qualification in Sight 16:30 South Africa: Seven Western Countries Warn of Rising Kidnapping Threat 16:09 Morocco: ACAPS Seeks Stronger Powers to Prevent Insurance Sector Crises 16:01 Brazil: Carlo Ancelotti Admits More Work Is Needed to Restore the National Team's Competitiveness 16:00 Apple Launches New App: Studying How People Use AI for Health 15:30 Morocco: MP Calls for Cigarette Prices to Reach 100 Dirhams per Pack 15:00 France vs Turkey: Zinédine Zidane Returns to Bordeaux as Les Bleus Secure Nations League Quarter-Final Spot 14:30 South Korea: AI Cheating Fears Prompt Tighter Security Ahead of University Entrance Exam 14:00 AI and Climate Change: UN Warns of Major Opportunities and Growing Environmental Risks 13:45 Israel’s Political Crisis: Eisenkot Accuses Netanyahu of Threatening Democracy 13:30 Anthropic: Three Major Challenges Ahead of Its Potential Stock Market Debut 13:15 GTA VI: Miami Transforms Into Vice City Ahead of the Highly Anticipated Launch 13:00 Morocco: Fuel Prices Drop as Gasoline and Diesel Become Cheaper at the Pump 12:45 Lebanon: US Considers Replacing UNIFIL With Fewer Than 100 International Observers 12:36 OPPO Unveils Photo and AI Innovations in Its New Find X10 Series 12:30 UK: Barrister Suspended for Four Months Over Antisemitic Social Media Posts 12:15 Morocco-US Relations: Mike Waltz to Visit Rabat for Talks on Regional Security and Strategic Cooperation 12:00 Francophonie: Secretary-General Election Postponed by One Year Amid Institutional Reforms 11:45 Amputee Football World Cup 2026: Morocco Beat the United States 2-1 to Reach the Round of 16 10:30 South Africa: Eight Men Shot Dead in KwaZulu-Natal Province 10:15 England: Three Lions Defeat Spain 3-2 in Madrid to End Champions’ Three-Year Unbeaten Run 10:00 Gaza Winter Crisis: Four Nations Demand Entry of 150,000 Tents for Displaced Families 09:56 AS FAR Women: Fouzi Lekjaa Congratulates the Moroccan Club on Its CAF Champions League Triumph 09:45 Angela Merkel: Former German Chancellor Criticizes Disproportionate International Scrutiny of Israel 09:30 Historic Gaza Tour: 20 UN Ambassadors Inspect Hamas Underground Infrastructure 09:15 France-Morocco Security Cooperation: French Police Praise Morocco Following Four Arrests of Internationally Wanted Suspects 09:00 Morocco's Currency Market: Dirham Gains 0.9% Against the Euro as Foreign Reserves Reach MAD 515.6 Billion 08:45 Rwanda: Five European Countries Plan to Establish Migrant Return Centres 08:30 Morocco Weather Forecast for November 16, 2026: Temperatures Reach 35°C in Some Regions

Germany approves first cannabis-based chronic pain medication Exilby

Wednesday 10 June 2026 - 08:52
By: Dakir Madiha
Germany approves first cannabis-based chronic pain medication Exilby

A biopharmaceutical company has secured regulatory approval in Germany and Austria for a cannabis-derived oral treatment targeting chronic lower back pain with neuropathic features. The product, Exilby (VER-01), becomes the first cannabis-based medicine explicitly authorized for chronic pain management in these markets. The company plans to pursue additional approvals in the United Kingdom and across the European Union, with availability for patients expected in the autumn.

The approval follows two large phase 3 randomized clinical trials involving more than 1,200 participants. One placebo-controlled study with 820 patients showed that VER-01 reduced pain intensity by an average of 1.9 points on an 11-point scale after 12 weeks of treatment. The effect persisted over a 12-month follow-up period, indicating sustained symptom control in a condition often resistant to long-term therapeutic improvement.

A second head-to-head trial conducted across several European countries compared VER-01 directly with opioid-based therapy in 384 patients. The results indicated stronger pain reduction and improved gastrointestinal tolerability for the cannabis-derived treatment. Researchers reported no evidence of dependence or withdrawal symptoms in either study, a finding that positions the drug as a potential alternative in long-term pain management strategies where opioid risks remain a major concern.

The company also confirmed progress in the United States regulatory pathway, where the treatment has received breakthrough therapy designation from the Food and Drug Administration. This status supports accelerated development for therapies addressing serious conditions. A further phase 3 trial is underway in the United States, with initial data expected in 2027 and a planned submission for market authorization in 2028. The treatment is delivered orally as liquid drops derived from a proprietary Cannabis sativa strain containing multiple bioactive compounds, with company leadership stating that it offers effective pain relief without addictive potential.


  • Fajr
  • Sunrise
  • Dhuhr
  • Asr
  • Maghrib
  • Isha

This website, walaw.press, uses cookies to provide you with a good browsing experience and to continuously improve our services. By continuing to browse this site, you agree to the use of these cookies.